SCHEMBL10058843

SCHEMBL10058843

Cn1ncc(-c2nc(-c3ccc(S(N)(=O)=O)cc3)co2)c1CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
ADRB3 P13945 2/20 0.40
KIF11 P52732 1/20 0.40
PTGS2 P35354 8/20 0.40
HSD11B1 P28845 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
STAT3 P40763 1/20 0.37
PTGS1 P23219 1/20 0.36
CYP2C9 P11712 1/20 0.36
PDPK1 O15530 2/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10060112 0.90 ADRB2 (0.36) S1PR1S1PR3ADRB2ADRB1ADRB3
SCHEMBL14973089 0.85 POLB (0.46) S1PR1KIF11CA12CA1CA2
SCHEMBL10060110 0.84 CA2 (0.45) KIF11PTGS2MEN1KMT2ACA1
SCHEMBL10060159 0.83 CA9 (0.46) S1PR1KIF11CA12CA1CA2
SCHEMBL14973155 0.77 PDE2A (0.34) S1PR1S1PR3
SCHEMBL14972931 0.77 CA9 (0.48) S1PR1MEN1KMT2ACA12CA1
SCHEMBL10058483 0.76 CA1 (0.47) MEN1KMT2ACA1CA2CA9
SCHEMBL10058991 0.76 PTGS2 (0.40) PTGS2MEN1KMT2ACA12CA1
SCHEMBL14972932 0.76 POLB (0.46) S1PR1STAT3
SCHEMBL10060160 0.75 CA9 (0.47) S1PR1MEN1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
WO-2012020820-A1 HETEROARYL-PYRAZOLE DERIVATIVE 大正製薬株式会社 (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A S1PR1 2686/4885S1PR3 1974/4885ADRB2 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.